Screening, diagnosis, and treatment of depression in patients with end-stage renal disease

被引:152
作者
Cohen, Scott D.
Norris, Lorenzo
Acquaviva, Kimberly
Peterson, Rolf A.
Kimmel, Paul L.
机构
[1] George Washington Univ, Med Ctr, Dept Med, Div Renal Dis & Hypertens, Washington, DC 20037 USA
[2] George Washington Univ, Dept Psychiat & Behav Sci, Washington, DC USA
[3] George Washington Univ, Dept Nursing Educ, Washington, DC USA
[4] George Washington Univ, Dept Psychol, Washington, DC 20052 USA
来源
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2007年 / 2卷 / 06期
关键词
D O I
10.2215/CJN.03951106
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Depression is common in patients with end-stage renal disease and has been linked to increased mortality. Screening for depression in the general medical population remains controversial; however, given the high prevalence of depression and its significant impact on morbidity and mortality, a strong case for depression screening in patients with end-stage renal disease can be made. Several studies have been performed to validate the more common depression screening measures in patients with chronic kidney disease. The Beck Depression Inventory, the Hamilton Rating Scale for Depression, the Nine-Question Patient Health Questionnaire, and the Center for Epidemiologic Studies Depression Scale are some of the measures that have been used to screen for depression in patients with end-stage renal disease. Data suggest a higher Beck Depression Inventory cutoff score, of >14 to 16, will have increased positive predictive value at diagnosing depression in patients with end-stage renal disease. There are limited data on the treatment of depression in this patient population. Pharmacotherapy, including selective serotonin reuptake inhibitors, can be used if deemed clinically indicated, and no active contraindication exists. There are even fewer data to support the role of cognitive behavioral therapy, social support group interventions, and electroconvulsive therapy for treatment of depression in patients with chronic kidney disease. Larger randomized, controlled clinical trials aimed at the treatment of depression in patients with end-stage renal disease are desperately needed.
引用
收藏
页码:1332 / 1342
页数:11
相关论文
共 100 条
[1]   SUICIDAL BEHAVIOR IN CHRONIC DIALYSIS PATIENTS [J].
ABRAM, HS ;
MOORE, GL ;
WESTERVELT, FB .
AMERICAN JOURNAL OF PSYCHIATRY, 1971, 127 (09) :1199-+
[2]   Dysthymia and cyclothymia in psychiatric practice a century after Kraepelin [J].
Akiskal, HS .
JOURNAL OF AFFECTIVE DISORDERS, 2001, 62 (1-2) :17-31
[3]  
[Anonymous], 1999, Drug Prescribing in Renal Failure
[4]   THE 5-HT3 ANTAGONIST ONDANSETRON REDUCES GASTROINTESTINAL SIDE-EFFECTS INDUCED BY A SPECIFIC SEROTONIN REUPTAKE INHIBITOR IN MAN [J].
BAILEY, JE ;
POTOKAR, J ;
COUPLAND, N ;
NUTT, DJ .
JOURNAL OF PSYCHOPHARMACOLOGY, 1995, 9 (02) :137-141
[5]   AN INVENTORY FOR MEASURING DEPRESSION [J].
BECK, AT ;
ERBAUGH, J ;
WARD, CH ;
MOCK, J ;
MENDELSOHN, M .
ARCHIVES OF GENERAL PSYCHIATRY, 1961, 4 (06) :561-&
[6]  
BLACK DW, 1987, J CLIN PSYCHIAT, V48, P438
[7]  
BLAZER DG, 1994, AM J PSYCHIAT, V151, P979
[8]   Fluoxetine in depressed patients on dialysis [J].
Blumenfield, M ;
Levy, NB ;
Spinowitz, B ;
Charytan, C ;
Beasley, CM ;
Dubey, AK ;
Solomon, RJ ;
Todd, R ;
Goodman, A ;
Bergstrom, RF .
INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE, 1997, 27 (01) :71-80
[9]   Temporal relation among depression symptoms, cardiovascular disease events, and mortality in end-stage renal disease: Contribution of reverse causality [J].
Boulware, L. Ebony ;
Liu, Yongmei ;
Fink, Nancy E. ;
Coresh, Josef ;
Ford, Daniel E. ;
Klag, Michael J. ;
Powe, Neil R. .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 1 (03) :496-504
[10]   Drug interaction of St John's wort with ciclosporin [J].
Breidenbach, T ;
Hoffmann, MW ;
Becker, T ;
Schlitt, H ;
Kiempnauer, J .
LANCET, 2000, 355 (9218) :1912-1912